Engineering designer beta cells with a CRISPR-Cas9 conjugation platform

Cas9 fusions partners are often limited to natural polypeptide chains at the Cas9 termni. Here the authors present a platform for site-specific and multiple-site conjugation to both termini and internal sites of Cas9, and they apply this platform to efficiently engineer insulin-producing β cells.

Guardado en:
Detalles Bibliográficos
Autores principales: Donghyun Lim, Vedagopuram Sreekanth, Kurt J. Cox, Benjamin K. Law, Bridget K. Wagner, Jeffrey M. Karp, Amit Choudhary
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Q
Acceso en línea:https://doaj.org/article/4fe0e563f9774b8ea8aa70b031449f72
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!